CSO
Altis Biosystems
Durham, North Carolina
I have spent the last 16 years in the biotech/pharmaceutical industry, currently serving as the Chief Scientific Officer at Altis Biosystems, a contract research organization focused on the development of novel cell-based models to support drug development. In this capacity, I oversee the development of Altis’ pipeline of innovative new model systems and applications. I previously served as VP of Research at Parion Sciences, a company focused on the development of small molecule drugs for a range of epithelial diseases. At Parion, I oversaw drug pharmacology, toxicology, and regulatory activities spanning the earliest stages of drug development. I advanced projects from target identification and proof-of-concept, through IND-enabling studies and first-in-human clinical trials.
I was trained as an epithelial cell biologist, completing my PhD in the Cell Biology Department at UNC Chapel Hill, where I studied pulmonary biology and the pathophysiology of lung diseases. I have authored 19 funded grant applications that collectively raised >$30M in non-dilutive funding in industry. I am a strong advocate for the training of young scientists and an active member of the scientific community, serving on NIH study sections for SBIR grants and training grants to provide career-growth opportunities for graduate students and post-doctoral fellows.
Rapid Fires: Novel Predictive Preclinical Models for Efficacy and Toxicology 2
Wednesday, October 25, 2023
3:00 PM – 4:00 PM ET
Applications of Human-Based Intestinal Cell Models in Preclinical Drug Development
Wednesday, October 25, 2023
3:00 PM – 3:15 PM ET